Literature DB >> 26628632

Efficacy of rituximab maintenance therapy for aggressive B-cell lymphoma depends on use of rituximab in induction therapy: a meta-analysis of randomized controlled trials.

Yasuhito Nannya1, Naoe Goto2, Masahito Shimizu2, Mitsuru Seishima3, Hisashi Tsurumi4.   

Abstract

Entities:  

Keywords:  aggressive lymphoma; meta-analysis; rituximab maintenance

Mesh：

Substances：

Year:  2015        PMID： 26628632      PMCID： PMC4666346          DOI： 10.3324/haematol.2015.136622

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Authors:  Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

2.  Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.

Authors:  Patrick J Stiff; Joseph M Unger; James R Cook; Louis S Constine; Stephen Couban; Douglas A Stewart; Thomas C Shea; Pierluigi Porcu; Jane N Winter; Brad S Kahl; Thomas P Miller; Raymond R Tubbs; Deborah Marcellus; Jonathan W Friedberg; Kevin P Barton; Glenn M Mills; Michael LeBlanc; Lisa M Rimsza; Stephen J Forman; Richard I Fisher
Journal:  N Engl J Med       Date:  2013-10-31       Impact factor: 91.245

3.  Suboptimal dosing of rituximab in male and female patients with DLBCL.

Authors:  Michael Pfreundschuh; Carsten Müller; Samira Zeynalova; Evelyn Kuhnt; Martin H J Wiesen; Gerhard Held; Tanja Rixecker; Viola Poeschel; Carsten Zwick; Marcel Reiser; Norbert Schmitz; Niels Murawski
Journal:  Blood       Date:  2013-12-02       Impact factor: 22.113

4.  Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.

Authors:  C Haioun; N Mounier; J F Emile; D Ranta; B Coiffier; H Tilly; C Récher; C Fermé; J Gabarre; R Herbrecht; F Morchhauser; C Gisselbrecht
Journal:  Ann Oncol       Date:  2009-06-30       Impact factor: 32.976

5.  Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.

Authors:  Michael Pfreundschuh; Viola Poeschel; Samira Zeynalova; Mathias Hänel; Gerhard Held; Norbert Schmitz; Andreas Viardot; Martin H Dreyling; Michael Hallek; Carsten Mueller; Martin H J Wiesen; Mathias Witzens-Harig; Lorenz Truemper; Ulrich Keller; Tanja Rixecker; Carsten Zwick; Niels Murawski
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

6.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Authors:  Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; Pierre Feugier; Réda Bouabdallah; John Vincent Catalano; Pauline Brice; Dolores Caballero; Corinne Haioun; Lars Moller Pedersen; Alain Delmer; David Simpson; Sirpa Leppa; Pierre Soubeyran; Anton Hagenbeek; Olivier Casasnovas; Tanin Intragumtornchai; Christophe Fermé; Maria Gomes da Silva; Catherine Sebban; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Myriam Mendila; Bertrand Coiffier; Hervé Tilly
Journal:  Lancet       Date:  2010-12-20       Impact factor: 79.321

7.  Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.

Authors:  Christian Gisselbrecht; Norbert Schmitz; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Noel J Milpied; John Radford; Nicolas Ketterer; Ofer Shpilberg; Ulrich Dührsen; Hans Hagberg; David D Ma; Andreas Viardot; Ray Lowenthal; Josette Brière; Gilles Salles; Craig H Moskowitz; Bertram Glass
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

8.  Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.

Authors:  Ulrich Jaeger; Marek Trneny; Helen Melzer; Michael Praxmarer; Weerasak Nawarawong; Dina Ben Yehuda; David Goldstein; Bilijana Mihaljevic; Osman Ilhan; Veronika Ballova; Michael Hedenus; Liang-Tsai Hsiao; Wing-Yan Au; Sonja Burgstaller; Gerhard Weidinger; Felix Keil; Christian Dittrich; Cathrin Skrabs; Anton Klingler; Andreas Chott; Michael A Fridrik; Richard Greil
Journal:  Haematologica       Date:  2015-04-24       Impact factor: 9.941

9.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279
  9 in total
  1 in total

Review 1.  Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma.

Authors:  Myrna Candelaria; Alfonso Dueñas-Gonzalez
Journal:  Ther Adv Hematol       Date:  2021-01-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.